Bio-Rad Laboratories (BIO.B) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed TransMedics Group (TMDX) over the past year, gaining 28.2% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -50.5% for BIO.B. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $2.74 billion), about 3.6 times the size, while TransMedics Group is growing revenue faster (+37.1% vs +0.7%).
On valuation, TransMedics Group trades at a lower trailing P/E (20.5x vs 46.3x for Bio-Rad Laboratories). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus 29.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | TMDX |
|---|---|---|
| Share price | $365.08 | $79.00 |
| Market cap | $9.76B | $2.74B |
| 1-day change | 0.00% | -2.55% |
| YTD return | +17.50% | -35.06% |
| 1-year return | +28.15% | -33.08% |
| 5-year return | -50.54% | +197.55% |
| P/E ratio (TTM) | 46.27 | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $7.89 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $605.49M |
| Revenue growth (YoY) | +0.65% | +37.13% |
| Net income (latest FY) | $759.90M | $190.29M |
| Gross margin | 51.87% | 59.92% |
| Operating margin | 1.83% | 17.93% |
| Net margin | 29.42% | 31.43% |
| 52-week high | $365.08 | $156.00 |
| 52-week low | $244.54 | $60.11 |
| Distance from 52-week high | 0.00% | -49.36% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +26.35% |
| Average volume | 6 | 820.41K |
| Shares outstanding | 5.06M | 34.68M |
| Employees | 7,450 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 3.6 times larger than TransMedics Group by market value ($9.76B vs $2.74B).
- BIO.B has outperformed TMDX by 61.2 percentage points over the past year.
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 20.5x trailing P/E).
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +0.65%).
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
BIO.B vs TMDX FAQ
Which is bigger, Bio-Rad Laboratories or TransMedics Group?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $2.74B for TransMedics Group (TMDX).
Which stock has performed better over the past year, BIO.B or TMDX?
BIO.B returned +28.15% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or TMDX?
TMDX has the lower trailing P/E at 20.5, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bio-Rad Laboratories and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.